Home
What is InSilicoTrials?
Optimization of medical device development
Use simulations to design and safely test new products in virtual patients
Modeling for dose selection, special populations, drug interactions
Estimate the right dose for the patient profile of interest
Integrated framework from data to treatment
Digitalize, integrate and analyze multidisciplinary data, e.g. clinical, images, genetic, etc.
Collaborative cloud platform
Share data, generate models, run simulations and analyze results with your project team
Reporting by guidelines
Present your simulation results following regulatory guidelines recommendations
Trusted Partnership
Reach out to a team of specialists who can assist you to overcome project hurdles and commercialize assets
Our business workflow
Partners
Research Centers
Have you developed a model which you want to make ready-to-use to a larger audience? Commercialize it through our platform
Hospitals
Do you have data that you want to digitize and structure in an integrated platform? Do you plan analysis and data mining? Look for our solutions
Companies
Are data and models part of your assets? Do you want to host or commercialize them in a secure and protected environment? Reach out to us
Software solution providers
Are simulation and data analysis tools your core business? Have you considered expanding your customers base with on-demand offers? Provide your solutions through our platform
Maximize your assets!
Users
Companies
We can help you achieve your goals using modeling and simulation tailored to customize your projects by leveraging scientific and technological advice.
Researchers & Clinicians
Are on-demand software and computing power what you need? Are you looking for an easy but sophisticated modeling and simulation tool? Answer your scientific questions through our platform.
Accelerate your project!
Why should I use it?
Develop and run your model
Easy access to models in Digital Library
Guaranteed data protection and cybersecurity
On-demand cloud computing
Ready-to-use computational environment
Option to report as by regulatory guidelines
Models and Simulations
NuMRis
Find out more about the interactions between implanted medical devices and the magnetic resonance imaging (MRI). With NuMRis - Numeric Magnetic Resonance implant testing, you will be able to simulate the behavior of the medical device (e.g. stent, hip prosthesis, 3D printed implant) during an MRI scan, to analyze the effects on the patient, and to quantify the dose and thermal outcomes due to the exposure.
QT/TdP Risk Screen
A new drug-induced QT prolongation risk assessment tool for the preclinical screening of your drug compounds. Provided by Universitat Politècnica de València (UPV, Valencia) and Fundació Institut Mar D'Investigacions Mèdiques (FIMIM, Barcelona). QT/TdP Risk Screen will help you to spot proarrhythmic risks and to identify safe concentration ranges for your drug compounds.
CONSELF
CONSELF is a cloud platform designed to allows healthcare companies to perform computational fluid dynamic (CFD) and finite element model (FEM) analysis through a Software as a Service (SaaS) access in pay-per-use mode. Now you can analyze your ideas, maximize performance, estimate durability and safety, evaluate stresses and deformations and much more in a flexible and cost-effective way. The platform can be used both as a general-purpose simulation solver or through guided workflows to perform In Silico reproduction of standardized testing to evaluate design alternatives and identify worst-case scenarios before prototyping.
"As simulation is now recommended by regulatory authorities and policy makers to accelerate approval without compromising with patient safety, it is essential to make available advanced simulation tools like ANSYS to the largest possible audience, no matter of their engineering simulation background. InSilicoTrials.com is the platform bridging the gap between software providers and clinical consumers."
Thierry Marchal
Global Industry Director Healthcare at ANSYS
"FDA's efforts in modeling and simulation are enabled through multiple collaborations with external parties that provide additional expertise and infrastructure to advance the development of these state-of-the-art technologies." - July 7, 2017 by FDA Voice
Scott Gottlieb
Former Commissioner of the U.S. Food and Drug Administration (FDA)
"QT/TdP Risk Screen is in line with current initiatives aiming to
define a new paradigm in cardiac safety like comprehensive in
vitro proarrhythmia assay (CiPA), where modeling and
simulation of the human cellular ventricular electrophysiology
plays a relevant role in the assessment of the proarrhythmic
risk of drugs."
Javier Saiz
Full Professor at Universitat Politècnica de València (UPV, Valencia)
Our network
